Clinical trials: Pharmacogenomic Testing
Major Depressive Disorder, PTSD
McLean and Genomind Prospective Study
This is a three month naturalistic prospective, randomized, open label study of pharmacogenetic testing and clinical outcomes in inpatients across diagnoses, including Treatment Resistant Depression (TRD) with or without…
- Trial name
- GPS (NCT03113890)
- Testing
- Phlebotomy - Folate, Cheek Swab, Self-report surveys
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mclean Hospital
Depression, Anxiety
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of…
- Trial name
- NCT02411123
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- AltheaDx
Schizophrenia, Schizoaffective Disorder
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT02566057
- Testing
- PGx testing guided treatment (PGT)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwell Health
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Chronic Kidney Disease, Hypertension
Genetic Testing to Understand and Address Renal Disease Disparities Across the United States Pharmacogenetic Substudy
This is a substudy of GUARDD-US (Genetic testing to Understand and Address Renal Disease Disparities across the United States, NCT04191824).
- Trial name
- GUARDD-US PGx (NCT06748040)
- Testing
- Timing of return of results
- Where
- 8 sites in United States
- Volunteers
- 1,874 people
- Sponsor
- Duke University
Depression
Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy
In this study at the Solothurn Psychiatric Clinic, the investigators compare the effectiveness and tolerability of antidepressant pharmacotherapy in three groups.
- Trial name
- PrePGx (NCT04507555)
- Testing
- Pharmacist-guided pharmacogenetic (PGx) testing for antidepressant selection and dosing, Standard care antidepressant selection and dosing
- Where
- 4 sites in Switzerland
- Volunteers
- 190 people
- Sponsor
- PD Dr. med. Thorsten Mikoteit
Oral Surgeries
Evaluation of Pharmacogenomics Testing to Precision Prescriptions in Periodontal Patients
The different patients responses to medications vary from dose effectiveness to adverse drug reaction (ADRs). ADRs affect outpatient settings as it account for estimated 1 million emergency department visits and over 3.5 million…
- Trial name
- NCT05467436
- Testing
- Local anesthetics, IV sedation drugs and analgesics.
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Augusta University
Healthy
Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum
The purpose of this study is to evaluate the use of personal genomic educational testing (PGET) on student knowledge and clinical skills surrounding pharmacogenomic testing to ensure it is of educational benefit to our student…
- Trial name
- NCT04889014
- Testing
- Personal genomic educational testing (PGET), No personal genomic educational testing (NPGET)
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Polypharmacy, Pharmacogenetics
Individual Risk Profiles for Adverse Drug Reactions in Geriatric Patients
This project will generate a prospective cohort of geriatric patients with polypharmacy which will be characterized for vulnerability profiles of adverse drug reactions.
- Conditions
- Polypharmacy, Pharmacogenetics, Pharmacogenomic Testing, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT05247814
- Testing
- Pharmacogenomic testing of a panel of important pharmacogenes to detect genetic variants and evaluate the association between genetically predicted and measured drug metabolism, Adverse Drug Reaction detection, Falls Efficacy Scale International (FES-I)
- Volunteers
- 2,000 people
- Sponsor
- RWTH Aachen University
Colorectal Cancer
Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic
Pharmacogenomics (PGx) studies the interactions between an individuals genes and medications. PGx testing identifies genes within an individual that may affect treatment, efficacy, and toxicity of drugs.
- Trial name
- CRCPGx (NCT03187184)
- Testing
- OneOme RightMed®
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Essentia Health
Depression, Anxiety
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or…
- Trial name
- NCT02878928
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- 17 sites in United States
- Volunteers
- 579 people
- Sponsor
- AltheaDx
All Malignancies, Children Being Treated for Catastrophic Illness
Pharmacogenetic Determinants Of Treatment Response In Children
To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates.
- Trial name
- NCT00730678
- Where
- United States
- Volunteers
- 8,800 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Depression, Depressive Disorder
Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE)
Depression is common among elderly with an estimated prevalence of 5%. Due to ageing the national burden will double in the coming decade.
- Conditions
- Depression, Depressive Disorder, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant, Intermediate Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Trial name
- CYSCE (NCT01778907)
- Testing
- Genotype information accompanied by a drug dosing advice
- Where
- 11 sites in Netherlands
- Volunteers
- 202 people
- Sponsor
- University of Groningen
Depression
Pharmacogenetic Testing in an Outpatient Population of Patients With Depression
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major…
- Trial name
- PGx-UPA (NCT02497027)
- Testing
- pharmacogenetic testing
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Admitted Multimorbid Patients
Implementation of Pharmacogenetic Testing in Hospital Wards
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
- Trial name
- FAGLIS (NCT04573491)
- Testing
- Pharmacogenetic test, Medication review
- Where
- Norway
- Volunteers
- 46 people
- Sponsor
- Hospital Pharmacy Enterprise, South Eastern Norway
Inflammatory Bowel Diseases, Crohn Disease
Cost-effectiveness of TPMT Pharmacogenetics
The purpose of this study is to determine whether thiopurine S-methyltransferase (TPMT) genotyping prior to thiopurine use is cost-effective in patients with inflammatory bowel disease (IBD) in need of immune suppression.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- TOPIC (NCT00521950)
- Testing
- TPMT genotyping; Drug: azathioprine or 6-mercaptopurine, azathioprine (AZA) or 6-mercaptopurine (6-MP)
- Where
- 3 sites in Netherlands
- Volunteers
- 853 people
- Sponsor
- ZonMw: The Netherlands Organisation for Health Research and Development
Use of Prescription Medications, Pharmacogenetic Testing
Trial of Preemptive Pharmacogenetics in Underserved Patients
This proposed research is relevant to human health because preemptive clinical pharmacogenetic testing may improve the personalization of drug therapy which should improve patient outcomes.
- Trial name
- ToPP-UP (NCT05141019)
- Testing
- Panel-based pharmacogenetic genotyping
- Where
- United States
- Volunteers
- 492 people
- Sponsor
- University of Florida
Polypharmacy
Effectiveness of PGx Testing
The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system.
- Trial name
- NCT04120480
- Testing
- Pharmacogenomic test
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Kaiser Permanente
Genetics of Drug Metabolism
Pharmacogenomic Testing Of the Elderly To Reduce Morbidity
The goal of the POETRY Registry is to determine whether data from Pharmacogenomic (PGx) Testing for elderly and disabled patients can help physicians manage patient medication regimens and assess if the testing has an effect on…
- Trial name
- POETRY (NCT02095769)
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 280,000 people
- Sponsor
- General Genetics Corporation
Obsessive Compulsive Disorder, Major Depressive Disorder
Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
The purpose of this study is to examine the feasibility, acceptability, and utility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 2D6 and 2C19 genes) prior to initiating treatment with an antidepressant…
- Conditions
- Obsessive Compulsive Disorder, Major Depressive Disorder, Anxiety
- Trial name
- PGX (NCT02855580)
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of Florida